Ismaili K, Abramowicz D, Adams B, Godefroid N, Lolin K, Schurmans T, Hall M, Janssen F
Départment de Néphrologie, Hémodialyse et Transplantation renale, H.U.D.E.R.F., Bruxelles.
Rev Med Brux. 2005 Nov-Dec;26(6):505-12.
Advances in immunosuppressive therapy over the past decade have led to dramatic improvements of patient and graft survival. The immunosuppression that is used is constantly evolving. The goal remains to find the best combination that will optimize long-term graft survival, while minimizing the adverse effects. It is likely that in the near future the results will even be improved further by the development of new medications with a better therapeutic index and the induction of transplant tolerance.
过去十年中免疫抑制疗法的进展使患者和移植物存活率得到了显著提高。目前所采用的免疫抑制方法也在不断发展。目标仍然是找到最佳组合，以优化移植物的长期存活，同时将不良反应降至最低。在不久的将来，通过开发具有更好治疗指数的新药以及诱导移植耐受，结果可能会进一步改善。
